Blog

Love Pharma Updates Microdoz Proposed Acquisition with Global Leader in Psychedelic Research

Mar 4 • 4 min read

LOVE Pharma Co. (CSE: LUV | FSE: G1Q0), the Company is pleased to announce updated details on the proposed Microdoz Therapy acquisition (originally announced in a press release on November 23, 2021), whereby Microdoz has engaged exclusively with researchers at Johns Hopkins University, the top psychedelic center in the World, located in the eastern United States,…

A Deeper Dive Into Novamind’s Q2 Financial Results

Mar 3 • 1 min read

Earlier this week, we reported on Novamind‘s quarterly results. You can read that here. But we wouldn’t be doing our job if we didn’t dive in deeper. So here is Adam’s video taking a closer look at Novamind, the market’s sentiment with the news, and comparisons with other industry companies that have made similar moves…

The Scientific Community is Investing Heavily in “The God Molecule”

Mar 3 • 3 min read

Medical research firms across the globe are turning their attention to 5-MeO-DMT—aka, “the God molecule”—and putting up the capital to prove it. The psychedelic compound—a close cousin of N, N-Dimethyltryptamine (DMT)—has become the focus of multiple studies over recent years… with a goal of bringing previously unavailable therapies to patients with severe mental health conditions,…

Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care

Mar 3 • 3 min read

Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP), a global leader in the development and delivery of psychedelic-assisted psychotherapy, today announced a strategic partnership with Cerebral, the fastest growing online mental health platform. The companies are launching a partnership where Cerebral clinicians can refer qualified clients to Field Trip Health’s ketamine assisted therapy, while Field Trip…

Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights

Mar 2 • 3 min read

Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2), a leading mental health company specialized in psychedelic medicine, reported its financial results for the three and six months ended December 31, 2021. All results are reported under International Financial Reporting Standards and in Canadian dollars, unless otherwise specified. “We’re pleased to report record high…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560